BiotechTube
Home/Magenta Therapeutics/Michael D. Clayman
MD

Michael D. Clayman

Former Chairman of the Board

Magenta Therapeutics

Therapeutic Areas

OncologyHematologyAutoimmune DiseasesGenetic Disorders

Magenta Therapeutics Pipeline

DrugIndicationPhase
MGTA-117Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes (MDS) (Conditioning)Phase 1/2
MGTA-145Multiple Myeloma / Lymphoma (Stem Cell Mobilization)Phase 2
MGTA-45Acute Leukemias (Conditioning)Preclinical
CD38-ADCAutoimmune Diseases (e.g., Lupus) (Conditioning)Discovery

Leadership Team at Magenta Therapeutics

JG
Jason Gardner
President, CEO, and Founder
MB
Michael Bell
Former Chief Medical Officer
JD
John Davis
Former Chief Operating Officer
MR
Michael R. Paglia
Former Chief Financial Officer
DS
David Scadden
Scientific Founder
DR
Derrick Rossi
Scientific Founder
BC
Boris Calderon
Scientific Founder
View full Magenta Therapeutics profile